A major Canadian online health-care platform is now offering its customers access to lower-cost semaglutide, a drug prescribed for Type 2 diabetes and commonly used for weight loss. Felix Health announced on Thursday that it will provide generic semaglutide at a price of $150 per month across Canada. The company reported that nearly 15,000 people have already registered for its waiting list for the weekly injectable medication, which helps manage blood sugar levels.
Health Canada Approves First Generic Versions
On April 28, Health Canada approved the first generic semaglutide injection, manufactured by India-based Dr. Reddy's Laboratories, making Canada the first G7 country to authorize a generic version of the drug. The regulatory body stated that the approval followed a thorough review of evidence demonstrating the drug's safety, efficacy, and quality. Just days later, on May 1, Health Canada approved a second generic version, produced by Toronto-based Apotex Inc.
Pricing Comparison: Brand-Name vs. Generic
According to Health Canada, generic medications can be 45% to 90% cheaper than their brand-name counterparts. Brand-name Ozempic treatments typically cost between $200 and $450 per month, depending on the province and provider. Felix Health noted that it is also offering lower pricing for existing Ozempic patients with the launch of the generic version. Experts anticipate that the cost will continue to decrease as more generic versions receive approval. Currently, seven additional applications for generic semaglutide are under review by Health Canada.
Felix Health's move aims to make the medication more accessible to Canadians, addressing both diabetes management and weight loss needs. The platform's initiative reflects a growing trend toward affordable generic alternatives in the pharmaceutical market.
